Vlad Herlea
Overview
Explore the profile of Vlad Herlea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matei E, Ciurea S, Herlea V, Dorobantu B, Vasilescu C
Chirurgia (Bucur)
. 2025 Mar;
120(1):117-124.
PMID: 40051324
Pancreatic metastases are very rare tumors comprising 2-5 % of all malignant tumors of the pancreas. Colorectal pancreatic metastases are rare - 1.7%. Clinical features: Three patients with colo-rectal pancreatic...
2.
Marin A, Herlea V, Bancu A, Giuglea C, Tapoi D, Ciongariu A, et al.
Medicina (Kaunas)
. 2025 Feb;
61(2).
PMID: 40005434
: Peripheral nerve defect regeneration is subject to ongoing research regarding the use of conduits associated with various cells or molecules. This article aims to correlate histopathological and clinical outcomes...
3.
Poenaru R, Milanesi E, Niculae A, Dobre A, Vladut C, Ciocirlan M, et al.
World J Gastrointest Oncol
. 2025 Jan;
17(1):98409.
PMID: 39817147
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive lethal malignancy with limited options for treatment and a 5-year survival rate of 11% in the United States. As for other types...
4.
Matei E, Ciurea S, Herlea V, Dumitrascu T, Vasilescu C
Medicina (Kaunas)
. 2025 Jan;
60(12.
PMID: 39768953
: The role of surgery in pancreatic metastases of renal cell carcinoma (PM_RCC) is highly controversial, particularly in the context of modern systemic therapies and the conflicting results of studies...
5.
Almarii F, Sajin M, Simion G, Dima S, Herlea V
J Pers Med
. 2024 Sep;
14(9).
PMID: 39338178
(1) Background: This study investigates the tumor immune microenvironment, focusing on immune cell distribution in lung adenocarcinoma. (2) Methods: We evaluated fifty cases of lung adenocarcinoma, and suitable areas for...
6.
Popescu I, Croitoru V, Croitoru-Cazacu I, Dudau A, Herlea V, Dima S, et al.
J Pers Med
. 2024 Jul;
14(7).
PMID: 39064004
Liquid biopsies can accurately identify molecular alterations in patients with colorectal cancer with high concordance with tissue analysis and shorter turnaround times. Circulating tumor (ct) DNA analysis can be used...
7.
Popescu I, Dudau A, Dima S, Herlea V, Croitoru V, Dinu I, et al.
Medicina (Kaunas)
. 2024 May;
60(5.
PMID: 38792879
Metastatic colorectal cancer requires a multidisciplinary and individualized approach. Herein, we reported the case of a young woman diagnosed with metastatic rectal cancer who received an individualized multimodal treatment strategy...
8.
Constantinescu D, Sorop A, Ghionescu A, Lixandru D, Herlea V, Bacalbasa N, et al.
Front Pharmacol
. 2024 Mar;
15:1363142.
PMID: 38510654
High-grade serous ovarian carcinoma (HGSOC) remains a medical challenge despite considerable improvements in the treatment. Unfortunately, over 75% of patients have already metastasized at the time of diagnosis. Advances in...
9.
Obrisca B, Mocanu V, Vornicu A, Jurubita R, Sorohan B, Dimofte G, et al.
PLoS One
. 2023 Dec;
18(12):e0296168.
PMID: 38134019
Background: We sought to evaluate the long-term effects of COVID-19 on renal function in patients with biopsy-proven kidney diseases. Methods: A total of 451 patients with biopsy-proven kidney disease and...
10.
Chivu-Economescu M, Herlea V, Dima S, Sorop A, Pechianu C, Procop A, et al.
Gastric Cancer
. 2023 Sep;
26(6):934-946.
PMID: 37668884
Background: In this study, we compared programmed death-ligand 1 (PD-L1) expression in primary tissue samples and its soluble form (sPD-L1) concentration in matched preoperative plasma samples from gastric cancer patients...